Targeted Protein Degradation (PROTACs and Molecular Glues)

Note: This page is educational and reflects public evidence through May 2026. It does not replace prescribing information, trial protocols, or clinical judgment.

TL;DR

Targeted protein degradation (TPD) uses drugs to make disease-driving proteins disappear rather than merely inhibit them. The best-known formats are PROTACs (bifunctional molecules that bring a target protein to an E3 ubiquitin ligase) and molecular glues (smaller molecules that stabilize a new interaction between a target and a ligase). In oncology, TPD matters because many cancer dependencies are transcription factors, scaffolds, fusion proteins, or mutant receptors that are hard to inhibit cleanly. On May 1, 2026, the FDA approved vepdegestrant (Veppanu) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy, making it the first FDA-approved PROTAC-type heterobifunctional protein degrader. Sources: [1], [2]

1. The core idea

Traditional small molecules usually work by occupying an active site and blocking a protein's function. Degraders work differently:

Target protein + degrader + E3 ligase
        ↓
Ternary complex
        ↓
Ubiquitination
        ↓
Proteasomal degradation
        ↓
Less target protein in the cell

This can remove both enzymatic and non-enzymatic functions. That is why degraders are attractive for targets where the problem is not just catalytic activity, but scaffolding, transcriptional regulation, protein-protein interaction, or mutant receptor signaling. Sources: [2]

2. PROTACs vs molecular glues

Feature	PROTAC	Molecular glue
Structure	Bifunctional: target binder + linker + E3 ligase binder	Usually smaller monofunctional molecule
Mechanism	Forces proximity between target and E3 ligase	Stabilizes or creates a target-ligase interface
Design	Rational but chemically bulky	Harder to design, often discovered phenotypically
Examples	ER degraders, BTK degraders, BCL6 degraders	IMiDs, CELMoDs, RBM39 degraders
Main challenge	Oral exposure, permeability, ternary-complex geometry	Selectivity, discovery predictability, degron biology

Both are part of the same larger field: pharmacologic control of protein abundance.

3. Why oncology cares

Cancer often depends on proteins that are hard to inhibit:

Hormone receptors — ER and androgen receptor can stay active through resistance mutations.
Transcriptional regulators — BCL6, MYC networks, BRD4, fusion oncoproteins.
Kinases with resistance mutations — degradation can remove kinase and scaffold functions.
Epigenetic regulators — chromatin complexes often rely on non-enzymatic scaffolding.
Mutant signaling nodes — degradation can sometimes bypass the need for perfect active-site inhibition.

The big therapeutic promise is not "any protein can be degraded." It is more specific: some cancer dependencies become druggable when removal is possible.

4. Clinical maturity

Approved

Vepdegestrant (Veppanu) — FDA-approved on May 1, 2026 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, detected by an FDA-authorized test, after progression following at least one endocrine therapy line. The FDA approval was based on VERITAC-2; in the ESR1-mutant population, median PFS was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant. Sources: [1]

Clinical-stage

Androgen receptor degraders — prostate cancer.
BTK degraders — B-cell malignancies and resistance to covalent/non-covalent BTK inhibitors.
BCL6 degraders — lymphoma.
BRD4/BET degraders — hematologic malignancies and solid tumors, with toxicity/selectivity challenges.
Molecular glues — hematologic malignancies, splicing factors, and neo-substrate discovery.

Preclinical / early translational

KRAS degraders, mutant-selective degraders, light-activated degraders, antibody-degrader conjugates, and tumor-conditional PROTACs.

5. What can go wrong

Hook effect — too much degrader can reduce ternary-complex formation.
Poor permeability — many PROTACs are large and polar.
E3 ligase expression — if the tumor lacks the recruited ligase, degradation may fail.
Resistance — target mutation, E3 pathway alteration, proteasome adaptation, drug efflux.
Toxicity — degrading a target in normal tissue can be worse than partial inhibition.
Biomarker mismatch — target expression does not guarantee dependency or degradation.
Off-target neosubstrates — especially relevant for molecular glues.

Degradation is powerful precisely because it is not subtle; that is also the safety risk.

6. What to measure

Good degrader programs need more than IC50:

DC50 — concentration causing 50% target degradation.
Dmax — maximum achievable degradation.
Kinetics — how fast target disappears and recovers.
Ternary-complex cooperativity — whether the degrader stabilizes target-ligase binding.
Proteomics — what else is degraded.
Functional rescue — does restoring the target reverse the phenotype?
Biomarkers — target abundance, E3 ligase expression, mutation status, downstream pathway shutdown.

For oncology, the clinical question is: does target degradation translate into tumor control without unacceptable normal-tissue toxicity?

7. What technologists can build

Ternary-complex modeling integrating protein structure, linker geometry, and E3 ligase context.
Degradation-aware ML models trained on DC50/Dmax/kinetics, not just binding affinity.
Proteomics pipelines for global degradation selectivity.
Biomarker dashboards combining target mutation, expression, E3 ligase expression, and pathway readouts.
Clinical-trial matching for degrader trials using mutation status and prior therapy.
Resistance atlases mapping escape mutations and E3 pathway alterations.

8. Brazilian context

Vepdegestrant's May 2026 FDA approval does not automatically mean ANVISA approval or SUS availability.
Near-term Brazilian relevance is molecular diagnostics: ESR1 mutation detection by ctDNA or tissue testing will determine whether eligible patients can be identified if/when the therapy becomes locally available.
Academic opportunities include proteomics, structural modeling, degrader selectivity studies, and real-world registry design once access begins.

References

U.S. Food and Drug Administration. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. May 1, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
Zhong G, Chang X, Xie W, Zhou X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther 2024;9:308. PMID 39500878. https://doi.org/10.1038/s41392-024-02004-x
Gough SM, Flanagan JJ, Teh J, et al. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clin Cancer Res 2024;30:3549-3563. PMID 38819400. https://doi.org/10.1158/1078-0432.CCR-23-3465
Kumar SH, Venkatachalapathy M, Sistla R, Poongavanam V. Advances in molecular glues: exploring chemical space and design principles for targeted protein degradation. Drug Discov Today 2024;29:104205. PMID 39393773. https://doi.org/10.1016/j.drudis.2024.104205

Targeted Protein Degradation (PROTACs and Molecular Glues) ​

TL;DR ​

1. The core idea ​

2. PROTACs vs molecular glues ​

3. Why oncology cares ​

4. Clinical maturity ​

Approved ​

Clinical-stage ​

Preclinical / early translational ​

5. What can go wrong ​

6. What to measure ​

7. What technologists can build ​

8. Brazilian context ​

See also ​

References ​